- Published on
Ophthalmology – Conjunctival Lymphoma
Conjunctival lymphoma is part of a spectrum of lymphoid tumors ranging from benign reactive hyperplasia to malignant lymphoma. It represents a form of extranodal lymphoma, meaning it arises outside lymph nodes, and accounts for a small proportion of all lymphomas. Within the eye, lymphoma can involve multiple structures including the conjunctiva, orbit, eyelid, uvea, retina, and vitreous. Importantly, conjunctival lymphoma may be the first manifestation of a systemic, potentially life-threatening lymphoma, making early recognition critical.
Clinically, it most often affects middle-aged to older adults and is rare in children. Patients may present with a painless, pink (“salmon-patch”) conjunctival mass, which is a key hallmark. Some individuals notice irritation, tearing, or a visible lesion, while others are completely asymptomatic. The tumor commonly arises in the fornix or midbulbar conjunctiva and can occasionally be multifocal or bilateral. Although many cases are initially localized, a significant proportion of patients may later develop systemic lymphoma, sometimes even decades after the ocular diagnosis.
The underlying pathophysiology is not fully understood, but many cases are classified as MALT (mucosa-associated lymphoid tissue) lymphoma. Chronic immune stimulation is believed to play a role, possibly related to infections such as Helicobacter pylori or Chlamydia psittaci, or autoimmune diseases like Sjögren’s syndrome or Hashimoto thyroiditis. Genetic abnormalities, including chromosomal translocations, have also been identified in some cases.
Diagnosis begins with clinical suspicion based on appearance, but definitive diagnosis requires biopsy. Histopathology helps distinguish between reactive hyperplasia, atypical lymphoid proliferation, and true malignant lymphoma. Additional evaluation includes CBC to rule out leukemia, as well as imaging—preferably orbital MRI—to assess for local extension. Because of the risk of systemic involvement, patients require long-term systemic surveillance, often with periodic imaging and medical evaluation.
Management depends on the extent and behavior of the tumor. Small, localized lesions may be treated with complete surgical excision combined with cryotherapy. If the lesion is diffuse or involves critical structures, an incisional biopsy followed by therapy is preferred. Treatment options include radiotherapy, which is highly effective due to the radiosensitive nature of lymphoma, as well as chemotherapy and immunotherapy (e.g., rituximab). Some clinicians also use antibiotics targeting suspected infectious triggers.
Long-term follow-up is essential, as recurrence or systemic progression can occur even many years later. Patients are typically monitored at least twice yearly with ocular exams and periodic systemic evaluation. Prognosis is generally favorable for localized disease, but the risk of systemic lymphoma varies—higher in bilateral cases than unilateral ones. Potential complications include ocular motility problems, ptosis, diplopia, or vision loss, particularly after treatment.
Conjunctival lymphoma is part of a spectrum of lymphoid tumors ranging from benign reactive hyperplasia to malignant lymphoma. It represents a form of extranodal lymphoma, meaning it arises outside lymph nodes, and accounts for a small proportion of all lymphomas. Within the eye, lymphoma can involve multiple structures including the conjunctiva, orbit, eyelid, uvea, retina, and vitreous. Importantly, conjunctival lymphoma may be the first manifestation of a systemic, potentially life-threatening lymphoma, making early recognition critical.
Clinically, it most often affects middle-aged to older adults and is rare in children. Patients may present with a painless, pink (“salmon-patch”) conjunctival mass, which is a key hallmark. Some individuals notice irritation, tearing, or a visible lesion, while others are completely asymptomatic. The tumor commonly arises in the fornix or midbulbar conjunctiva and can occasionally be multifocal or bilateral. Although many cases are initially localized, a significant proportion of patients may later develop systemic lymphoma, sometimes even decades after the ocular diagnosis.
The underlying pathophysiology is not fully understood, but many cases are classified as MALT (mucosa-associated lymphoid tissue) lymphoma. Chronic immune stimulation is believed to play a role, possibly related to infections such as Helicobacter pylori or Chlamydia psittaci, or autoimmune diseases like Sjögren’s syndrome or Hashimoto thyroiditis. Genetic abnormalities, including chromosomal translocations, have also been identified in some cases.
Diagnosis begins with clinical suspicion based on appearance, but definitive diagnosis requires biopsy. Histopathology helps distinguish between reactive hyperplasia, atypical lymphoid proliferation, and true malignant lymphoma. Additional evaluation includes CBC to rule out leukemia, as well as imaging—preferably orbital MRI—to assess for local extension. Because of the risk of systemic involvement, patients require long-term systemic surveillance, often with periodic imaging and medical evaluation.
Management depends on the extent and behavior of the tumor. Small, localized lesions may be treated with complete surgical excision combined with cryotherapy. If the lesion is diffuse or involves critical structures, an incisional biopsy followed by therapy is preferred. Treatment options include radiotherapy, which is highly effective due to the radiosensitive nature of lymphoma, as well as chemotherapy and immunotherapy (e.g., rituximab). Some clinicians also use antibiotics targeting suspected infectious triggers.
Long-term follow-up is essential, as recurrence or systemic progression can occur even many years later. Patients are typically monitored at least twice yearly with ocular exams and periodic systemic evaluation. Prognosis is generally favorable for localized disease, but the risk of systemic lymphoma varies—higher in bilateral cases than unilateral ones. Potential complications include ocular motility problems, ptosis, diplopia, or vision loss, particularly after treatment.
0 Comments
